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Costochondral cartilage growth zone
chondrocytesWnt5a and 1α,25(OH)2D3 are important regulators of endochondral ossiﬁcation. In osteoblasts and growth plate
chondrocytes, 1α,25(OH)2D3 initiates rapid effects via its membrane-associated receptor protein disulﬁde isom-
erase A3 (Pdia3) in caveolae, activating phospholipase A2 (PLA2)-activating protein (PLAA), calcium/calmodulin-
dependent protein kinase II (CaMKII), and PLA2, resulting in protein kinase C (PKC) activation.Wnt5a initiates its
calcium-dependent effects via intracellular calcium release, activating PKC and CaMKII. We investigated the re-
quirement for components of the Pdia3 receptor complex in Wnt5a calcium-dependent signaling. We deter-
mined that Wnt5a signals through a CaMKII/PLA2/PGE2/PKC cascade. Silencing or blocking Pdia3, PLAA, or
vitamin D receptor (VDR), and inhibition of calmodulin (CaM), CaMKII, or PLA2 inhibitedWnt5a-induced PKC ac-
tivity.Wnt5a activated PKC in caveolin-1-silenced cells, butmethyl-beta-cyclodextrin reduced its stimulatory ef-
fect. 1α,25(OH)2D3 reduced stimulatory effects of Wnt5a on PKC in a dose-dependent manner. In contrast,
Wnt5a had a biphasic effect on 1α,25(OH)2D3-stimulated PKC activation; 50 ng/ml Wnt5a caused a 2-fold in-
crease in 1α,25(OH)2D3-stimulated PKC but higher Wnt5a concentrations reduced 1α,25(OH)2D3-stimulated
PKC activation. Western blots showed that Wnt receptors Frizzled2 (FZD2) and Frizzled5 (FZD5), and receptor
tyrosine kinase-like orphan receptor 2 (ROR2) were localized to caveolae. Blocking ROR2, but not FZD2 or
FZD5, abolished the stimulatory effects of 1α,25(OH)2D3 on PKC and CaMKII. 1α,25(OH)2D3membrane receptor
complex components (Pdia3, PLAA, caveolin-1, CaM) interacted with Wnt5a receptors/co-receptors (ROR2,
FZD2, FZD5) in immunoprecipitation studies, interactions that changed with either 1α,25(OH)2D3 or Wnt5a
treatment. This study demonstrates that 1α,25(OH)2D3 and Wnt5a mediate their effects via similar receptor
components and suggests that these pathways may interact.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Endochondral ossiﬁcation encompasses multiple events during
which the embryonic cartilaginous template of long bones is gradually
calciﬁed and replaced by bone [1]. Previous reports by our lab and
other groups have suggested that a complex network of interacting sig-
naling pathways induced by hormones and growth factors also regulate
post-natal growth plate chondrocytes and endochondral bone forma-
tion [2–5]. However, limited information is available on the molecular
basis of these interactions.
In the present study, we focus on inter-relation between two path-
ways involved in regulation of post-natal growth plate cartilage and
osteoblast maturation: 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3]inia Commonwealth University,
1 804 828 0190; fax: +1 804membrane-mediated signaling and non-canonical Wnt5a calcium-
dependent signaling. 1α,25(OH)2D3 induces its effects via two mecha-
nisms: classical vitamin D receptor (VDR) signaling and the more re-
cently described calcium-dependent membrane-mediated pathway
[6–8]. In the membrane-mediated pathway, 1α,25(OH)2D3 initiates its
effects via its speciﬁc membrane-associated receptor protein disulﬁde
isomerase family A, member 3 (Pdia3, also known as ERp60, ERp57,
Grp58, and 1,25-MARRS) [9,10] located in caveolae, which are 50–
100 nm lipid rafts highly enriched with cholesterol and glycosphingo-
lipids [11]. Caveolae are characterized by caveolin coat proteins
(Cav-1, Cav-2, Cav-3) that serve as signaling platforms for several
steroid hormones [11]. Upon binding to Pdia3, 1α,25(OH)2D3 induces
interactions between Pdia3 and phospholipase-A2 (PLA2)-activating
protein (PLAA) [12], stimulating increased calcium/calmodulin-
dependent protein kinase II (CaMKII) activity in costochondral growth
zone chondrocytes (GC) and MC3T3-E1 osteoblast-like cells [13]. PLA2
is activated [14], producing lysophospholipid and releasing arachidonic
acid (AA) [15] that is further processed into prostaglandin E2 (PGE2).
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increase cyclic AMP [16], which results in downstream PKC and ERK1/2
activation [17]. Together with Gαq, lysophospholipid activates
phosphatidylinositol-speciﬁc phospholipase C beta (PLCβ), generat-
ing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) [14,
15]. DAG binds PKCα, recruiting it to the plasma membrane [18].
IP3 activates the release of calcium ions required for PKCα activa-
tion from the endoplasmic reticulum.
1α,25(OH)2D3 stimulates differentiation of growth zone chondro-
cytes and osteoblasts, increasing alkaline phosphatase speciﬁc activ-
ity [16] and in the case of osteoblasts, by increasing production of
osteopontin [9]. While the VDR mediates many of the effects of
1α,25(OH)2D3 on these cells, Pdia3-dependent signaling has been
shown to mediate the effects of the vitamin D metabolite on these
two markers of osteoblast differentiation. Pdia3 gene knockout results
in embryonic lethality [19,20] and as a result, a deﬁnitive demonstration
of its role has not been possible. However, conditional knockout of
Pdia3 in the intestinal epithelium results in severely blunted Ca2+ uptake
in response to 1α,25(OH)2D3 [21], conﬁrming its involvement in
1α,25(OH)2D3 dependent actions. Moreover, Pdia3+/− mice exhibit
a long bone phenotype [19], further demonstrating the importance
of this 1α,25(OH)2D3 receptor in skeletal development.
Wnts are signaling molecules that also regulate skeletal development
andmaintenance [22,23]. In the growth plate,Wnt5a expression is low in
the reserve zone, increased in proliferative and prehypertrophic zones,
and decreased in the hypertrophic region [24].Wnt5a plays an important
role in transition of chondrocytes between growth plate zones. Growth
plates of Wnt5a−/−mice exhibit delayed chondrocyte hypertrophy, sug-
gesting that Wn5a plays a critical role in promoting hypertrophy [25].
Wnt5a is also expressed by osteoblasts at the interface between calciﬁed
cartilage and metaphyseal bone and it has been shown to promote oste-
oblast maturation in vitro [5,26]. Osteoblasts isolated from Wnt5a−/−
mice exhibit down-regulation of osteoblastic differentiation markers in-
cluding runt related transcription factor 2, osterix and alkaline phospha-
tase [27] compared to wild type cells, suggesting Wnt5a regulates bone
formation. This is supported by histological analysis of long bones of
Wnt5a−/−mice, which exhibit signiﬁcantly delayed chondrocyte hyper-
trophy and skeletal ossiﬁcation compared to wild type mice [25]. Wnt5a
induces its effects via several known receptors and co-receptors including
Frizzled2 (FZD2), Frizzled5 (FZD5), and receptor tyrosine kinase-like or-
phan receptor 2 (ROR2), activating intracellular release of calcium, there-
by activating PLC, PKC, CaMKII and calcineurin [28–32].
Although 1α,25(OH)2D3 and Wnt5a both regulate osteoblast and
chondrocyte maturation and signal via calcium-dependent mechanisms,
little is known about the role of components of the 1α,25(OH)2D3
membrane-associated receptor complex in Wnt5a calcium-dependent
signaling. The purpose of this studywas to determine if the same receptor
complex and pathway signaling proteins that are critical for the
1α,25(OH)2D3 membrane-mediated pathway via Pdia3 are also im-
portant for Wnt5a calcium-dependent signaling. To address this
question, we ﬁrst veriﬁed Wnt5a-dependent activation of CaMKII,
PLA2, PKC, and PGE2 release in MC3T3-E1 osteoblast-like cells and
GC cells. Next, we determined the role of the 1α,25(OH)2D3 activat-
ed Pdia3-dependent membrane receptor complex and its down-
stream signaling proteins in Wnt5a-stimulated PKC activation
using the MC3T3-E1 cell model. Finally, we determined the interac-
tions between the 1α,25(OH)2D3 membrane-receptor complex and
Wnt5a receptors with or without 1α,25(OH)2D3 or Wnt5a treat-
ment in MC3T3-E1 cells.
2. Materials and methods
2.1. Reagents
Recombinant human/mouse Wnt5a was purchased from R&D
Systems (Minneapolis, MN). 1α,25(OH)2D3 and PLAA were purchasedfrom Enzo Life Sciences (Plymouth Meeting, PA). The anti-PLAA poly-
clonal antibody was designed and developed by Strategic Diagnostics
Inc. (Newark, DE) [12]. Rabbit antiserumagainst theN-terminal peptide
of Pdia3 was purchased from Alpha Diagnostic International (San
Antonio, TX) [33]. A polyclonal antibody to Cav-1 was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). ROR2 polyclonal antibody
was fromCell Signaling Technology (Danvers, MA). Frizzled2 polyclonal
antibody and Frizzled5 polyclonal antibody were from Abcam (San
Francisco, CA).Monoclonal antibody to CaMwas fromMillipore (Billerica,
MA). Myristoylated calmodulin kinase IINtide (mer-CaMKIINtide)
peptide was from EMD Biosciences (Billerica, MA) and arachidonyl
triﬂuoromethyl ketone (AACOCF3) was from Abcam. All other reagents
were purchased from Sigma Aldrich (St. Louis, MO) unless speciﬁed.
2.2. Cell culture
Wild type (WT) mouse MC3T3-E1 subclone 4 osteoblast-like cells
(CRL-2593) were purchased from ATCC (Manassas, VA, USA). Stably
silenced MC3T3-E1 cell lines for Pdia3 (shPdia3), PLAA (shPlaa),
Cav-1 (shCav-1), VDR (shVdr), CaMKII-α (shCamk2a), and CaMKII-β
(shCamk2b) were generated and characterized by our lab previously [9,
12,34]. Cells were plated at 10,000 cells/cm2 and cultured in Minimum
Essential Medium Alpha (α-MEM) (Life Technologies, Carlsbad, CA) con-
taining 10% fetal bovine serum (FBS) (Hyclone, Waltham, MA) and 1%
penicillin–streptomycin (P/S) (Life Technologies). Osteoblastic differenti-
ation ofMC3T3-E1 cells was induced by culture inα-MEM supplemented
with 10% FBS, 1% P/S and 50 μg/ml ascorbic acid 24 h after plating, and
then every 48 h thereafter [35].
GC cells were isolated from costochondral cartilage of 100–125 g
male Sprague–Dawley rats (Harlan, Indianapolis, IN). Rats were at the
end of their adolescent growth spurt; therefore, their long bones were
growing at a reduced rate. The culture system used in this study was
described previously in detail [36,37]. Brieﬂy, fourth passage cultures
of GC chondrocytes were plated at 10,000 cells/cm2 and cultured in
Dulbecco's modiﬁed Eagle's medium (Mediatech) containing 10% FBS,
1% P/S, and 50 μg/ml ascorbic acid.
All cellswere cultured at 37 °Cwith 5%CO2 and 100% humidity. Con-
ﬂuent cultures were treated for experiments as described below. The
approximate density of MC3T3-E1 osteoblast-like cells at the time of
treatment was 80,000 cells/cm2.
2.3. Time course and dose–response of PKC activity to Wnt5a
To assess the dose-dependent effects ofWnt5a on PKC, GC cells were
treated for 9 min and MC3T3-E1 cells were treated for 15 min with 50,
125 and 200 ng/mlWnt5a [26,38], time points previously demonstrated
to be optimal for activation of PKC by 1α,25(OH)2D3 in these cell types
[12,39]. After treatment, cell layers were washed with phosphate buff-
ered saline (PBS) and then were lysed in RIPA buffer (20 mM Tris–
HCl, 150mMNaCl, 5mMdisodiumEDTA, 1%Nonidet P-40). PKC activity
wasmeasured in cell layer lysates using a commercially available kit fol-
lowingmanufacturer's instructions (GE Healthcare, Piscataway, NJ) and
data were normalized to total protein (Pierce BCA Protein Assay, Ther-
mo Fisher Scientiﬁc, Waltham, MA).
Next, the time course of PKC activation byWnt5awas examined. GC
cells and MC3T3-E1 cells were treated with 125 ng/ml [26,38] Wnt5a
for 6, 9, 15, or 30 min. PKC activity was measured as described above.
2.4. Time course of Wnt5a effect on CaMKII activity
GC and MC3T3-E1 cells were treated for 6, 9, 15, and 30 min with
125 ng/ml Wnt5a and cell layer lysates were assayed for CaMKII activity.
CaMKII activity was measured using a commercially available assay fol-
lowing manufacturer's instructions (SignaTECT® Calcium/Calmodulin-
Dependent Protein Kinase Assay System, Promega, Madison,WI). CaMKII
activity was normalized to total protein in the cell lysate.
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GC and MC3T3-E1 cells were treated for 6, 9, 15, or 30 min with
125 ng/mlWnt5a. After washing the cell layers with PBS, the cell layers
were lysed and assayed for PLA2 activity using a commercially available
kit (cPLA2 Assay kit, 765021, Cayman Chemical, Ann Arbor, MI). PLA2
data were normalized to total protein.2.6. Time course of Wnt5a effect on PGE2 release
GC and MC3T3-E1 cells were treated for 6, 9, 15, and 30 min with
125 ng/ml Wnt5a. At the end of incubation, conditioned media were
acidiﬁed and PGE2 was measured using a commercially available kit
(Prostaglandin E2 [125I]-RIA kit, Perkin Elmer, Waltham, MA). PGE2
levels were normalized to total DNA (Quant-iTTM PicoGreen® dsDNA
Assay kit, Life Technologies).2.7. Role of vitamin D signaling components inWnt5a-induced PKC activity
Based on the results of time-course and dose–response studies, the
treatment conditions resulting in the highest PKC activity (125 ng/ml
Wnt5a for 9 min in GC cells and 125 ng/ml Wnt5a for 15 min in
MC3T3-E1 osteoblast-like cells) were selected for subsequent experi-
ments unless speciﬁed in the text.
To determine the effects of Pdia3, Vdr, and Cav1 silencing onWnt5a-
induced PKC activity, wild type (WT), shPdia3, shVdr, and shCav-1 cells
were treated with Wnt5a and PKC measured. These results were
conﬁrmed using Pdia3 and VDR blocking antibodies in GC chondrocytes
and MC3T3-E1 cells. Cells were pretreated with either anti-Pdia3 or
anti-VDR antibodies for 30 min, and PKC activity measured after
Wnt5a treatment.
Methyl-beta-cyclodextrin (β-CD) disrupts lipids rafts and caveolae
by binding cholesterol and removing it from the plasma membranes.
To determine the effects of caveolae destruction on PKC activation,
MC3T3-E1 cells were treated with 10 mM of β-CD for 30 min in
serum-free media, as described previously [40]. At the end of incuba-
tion, cell layers were rinsed with serum free media. Cells were then
treated withWnt5a and cell layer lysates were assayed for PKC activity.2.8. Role of calmodulin in Wnt5a-induced PKC activity
MC3T3-E1 cells were pre-treated with 0.1, 1, or 10 μM calmodulin
inhibitor W-7 for 30 min [41], then cells were treated with Wnt5a for
15 min and cell layer lysates were assayed for PKC activity. To investi-
gate the effect of CaMKII inhibition on 1α,25(OH)2D3-dependent PKC
activation, MC3T3-E1 cells were treated for 30 min with 1.25, 2.5, and
5 μM CaMKII peptide-inhibitor mer-CaMKIINtide [42] followed by
Wnt5a. Cell layer lysates were assayed for PKC activity. To investigate
the effects of Camk2a and Camk2b silencing on Wnt5a-stimulated PKC
activation, conﬂuent WT, shCamk2a, and shCamk2a MC3T3-E1 cells
were treated withWnt5a. Cell layer lysates were assayed for PKC.2.9. Role of PLAA in Wnt5a-induced PKC activity
Cells were pretreatedwith anti-PLAA antibody (PLAA Ab) for 30min
followed by Wnt5a for 15 min. Cell layer lysates we assayed for PKC
activity. To conﬁrm these ﬁndings, PKC activity was measured in WT
and shPlaaMC3T3-E1 cells afterWnt5a treatment. To investigate the ef-
fects of PLA2 inhibition on PKC activity, MC3T3-E1 osteoblast-like cells
were pretreated with 0.1, 1, and 10 μM AACOCF3 for 30 min followed
byWnt5a. PKC activity was measured in cell layer lysates. AACOCF3
has been shown in other studies to inhibit PLA2 in these cells [43].2.10. Effects of Wnt5a and 1α,25(OH)2D3 co-treatment on regulation of
PKC activity
MC3T3-E1 cells were treated with 0, 10−10, 10−9, or 10−8 M
1α,25(OH)2D3. Wnt5awas added to one-half of the cultures at the con-
centration of 125 ng/ml. At the end of the 15-min incubation, cell layer
lysates were assayed for PKC. To assess the effects of Wnt5a in
1α,25(OH)2D3 regulation of PKC activity, MC3T3-E1 cells were treated
with 10−8 M 1α,25(OH)2D3 and 0, 50, 87.5 or 125 ng/ml Wnt5a for
15 min. At the end of the incubation, the cell layer lysates were assayed
for PKC.
2.11. Roles of ROR2, FZD2 and FZD5 in 1α,25(OH)2D3-induced PKC activity
MC3T3-E1 cells were pretreatedwith anti-Frizzled2 (FZD2Ab), anti-
Frizzled5 (FZD5 Ab), or anti-ROR2 (ROR2 Ab) antibodies for 30min, and
were then treated with 10−8 M 1α,25(OH)2D3 for 15 min. PKC activity
was measured in cell layer lysates.
2.12. Role of ROR2 in 1α,25(OH)2D3-induced CaMKII activity
MC3T3-E1 cells were pretreated with anti-ROR2 antibodies for
30 min, and were then treated with 10−8 M 1α,25(OH)2D3 for
15 min. CaMKII activity was measured in cell layer lysates.
2.13. Role of ROR2 on PLAA-induced CaMKII activity
MC3T3-E1 osteoblasts were pretreated with anti-ROR2 antibodies
for 30 min, and were then treated with 10−6 M PLAA peptide for
15 min. CaMKII activity was measured in cell layer lysates.
2.14. Caveolae isolation
Pdia3 exists in plasma membrane caveolae of osteoblasts [9]. To de-
termine the plasma membrane localization of FZD2, FZD5 and ROR2,
plasma membranes and caveolae were isolated using a detergent-free
method as described previously [44]. Brieﬂy, conﬂuent MC3T3-E1 cul-
tures were harvested by scraping while in isolation buffer (0.25 M su-
crose, 1 mM EDTA, 20 mM Tricine, pH 7.8) and were homogenized
using a tissue grinder (20 strokes; 10 strokes clockwise and 10 strokes
counter-clockwise). Homogenates were centrifuged at 20,000g for
10 min. The supernatant was collected and layered on top of isolation
buffer containing 30% Percoll® (GEHealthcare, Piscataway, NJ). The pel-
let, including nucleus, mitochondria, and endoplasmic reticulum,
was discarded. Samples were centrifuged at 84,000g for 30 min.
Syringe needles (18G) were used to collect the plasma membrane
fraction from the gradient column. The isolated fraction was layered
over a 10%–20% OptiPrep gradient (Sigma Aldrich, St. Louis, MO),
then centrifuged at 52,000g for another 4 h. Plasma membrane
sub-fractions were collected from the tube, resulting in isolation of
thirteen fractions. Caveolae were observed as an opaque band that was
collected in fraction 3.
2.15. Western blots
Whole cell layer lysates and plasma membrane fractions (50 μg
protein) were loaded onto 4%–20% Mini-PROTEAN® TGX™ precast
polyacrylamide gels (Bio-Rad, Hercules, CA). Proteins were trans-
ferred to low-ﬂuorescence PVDF membranes (Bio-Rad) using a
Trans-Blot® Turbo™ Transfer System (Bio-Rad). Membranes were
incubated with blocking buffer (LI-COR, Lincoln, NE) for 1 h. Subse-
quently, the membranes were incubated with antibodies against Cav-1,
FZD2, FZD5, and ROR2 overnight. The next day, the membranes were
incubated for 1 h with IRDye 800CW conjugated goat anti-rabbit IgG sec-
ondary antibodies (LI-COR) in blocking buffer containing 0.2% Tween-20,
and 0.01% SDS. Following three washes with PBS containing 0.05%
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Infrared Imaging System.2.16. Effects of 1α,25(OH)2D3 andWnt5a on receptor complex interactions
MC3T3-E1 cells were treated with 10−8 M 1α,25(OH)2D3 or its
vehicle (ethanol), or 125 ng/ml Wnt5a or its vehicle (cell culture
medium) for 15 min. At the end of treatment, cell layers were
washed with PBS and cell layers were lysed in RIPA buffer con-
taining 100 mM sodium ﬂuoride, protease inhibitor cocktail, and
1 mM phenylmethylsulfonyl ﬂuoride. Protein samples (500 μg)
were pre-cleared by incubation in 5 μg of rabbit IgG conjugated
to Dynabeads® Protein A (Life Technologies) at 4 °C for 1 h. The
beads were separated from solution using a magnet. To immunopre-
cipitate Pdia3, PLAA, Cav-1 and CaM protein complexes, anti-Pdia3,
anti-PLAA, anti-Cav-1, and anti-CaM antibodies were covalently
coupled to the Dynabeads Protein A according to the manufacturer's
protocol. Pre-cleared protein samples were mixed with antibody
coated Dynabeads and incubated at 4 °C overnight with continuous
agitation. Dynabeads were recovered using a magnet and were
washed three times with 0.05% Tween-20 in PBS. Precipitated pro-
teins were eluted in elution buffer, then diluted in Tris–glycine
SDS sample loading buffer (Bio-Rad) and boiled for 5 min. Immuno-
precipitated samples were examined by Western blot (ONE-HOUR
Western™ Fluorescent Kit, Genscript, Piscataway, NJ).2.17. Statistical analysis
For each experiment, data points represent the mean ± standard
error of themean (SEM) of six individual cultures, per variable. Each ex-
perimentwas repeated at least three times to ensure validity of the data.
Statistical signiﬁcancewas assessed by analysis of variance and post hoc
testing performed using Bonferroni's modiﬁcation of Student's t-test for
multiple comparisons (GraphPad Prism, GraphPad Software, Inc., San
Diego, CA). P-values b0.05 were considered signiﬁcant.3. Results
3.1. Wnt5a rapidly activates PKC, CaMKII, and PLA2 and triggers PGE2
release
Wnt5a regulated the activity of PKC in GC and MC3T3-E1 cells
in a dose- and time-dependent manner. Similarly, the effects of
Wnt5a on CaMKII and PLA2 activities and PGE2 release were time-
dependent and rapid. Wnt5a protein increased PKC-speciﬁc activity
in a dose-dependent manner in GC cells with the highest stimula-
tory effects of the peptide observed at 125 ng/ml concentration
(Fig. 1A). Wnt5a activated PKC in a dose-dependent manner in
MC3T3-E1 cells, with the highest stimulatory effect observed at
125 ng/ml (Fig. 1B). Wnt5a activated PKC in GC cells within 9 min
of treatment, and PKC remained signiﬁcantly higher than control
at 15 and 30 min after treatment (Fig. 1C).
We further assessed whether Wnt5a acts on cells by a mechanism
similar to that used by 1α,25(OH)2D3. Wnt5a increased CaMKII activity
at 9 and 15min after treatment in GC chondrocytes (Fig. 1D).Wnt5a in-
creased PLA2 activity (Fig. 1E) and PGE2 release (Fig. 1F) in GC cells at
both 9 min and 30 min after treatment. Similarly, Wnt5a caused a
rapid increase in PKC activity in MC3T3-E1 cells at 9 min that remained
elevated until 30min, with a peak at 15 min (Fig. 1G). Wnt5a increased
CaMKII activity at 6, 9, and 30 min in MC3T3-E1 osteoblast-like cells
(Fig. 1H). Similarly, the effect of Wnt5a on PLA2 activity (Fig. 1I) and
PGE2 release (Fig. 1J) was time-dependent and signiﬁcant increases
were observed at 9 and 30 min after the treatment.3.2. Pdia3, VDR, and lipid rafts, but not Cav-1, are required for the PKC
activation in response to Wnt5a
Pdia3, VDR, and plasma membrane lipid raft structures were
involved in Wnt5a-stimulated rapid activation of PKC in MC3T3-E1
osteoblasts, while Cav-1 was not required. Unlike WT cells, shPdia3
osteoblasts did not increase in PKC activity in response to Wnt5a
(Fig. 2A).Wnt5a stimulated PKC activity in shVdr cells was signiﬁcantly
lower than inWT cells (Fig. 2B). However, Wnt5a failed to increase PKC
in shCav-1 osteoblasts (Fig. 2C). Likewise, Pdia3 antibody (Fig. 2D) and
VDR antibody (Fig. 2E) signiﬁcantly reduced the Wnt5a-induced in-
crease in PKC activity in MC3T3-E1 cells. Although Wnt5a stimulated
PKC activity in cells pretreated with lipid raft disruptor β-CD, the in-
crease was signiﬁcantly lower when compared to the β-CD untreated
group (Fig. 2F).
3.3. CaM, CaMKII-α, PLAA, and PLA2 are required for the rapid activation of
PKC in response to Wnt5a
In MC3T3-E1 cells, Wnt5a-stimulated activation of PKC depends on
upstreamactions of CaM, CaMKII-α, PLAA, and PLA2. Calmodulin inhibitor
W-7 blocked activation of PKC in response to Wnt5a at 1 and 10 μM, but
not at 0.1 μM(Fig. 3A).mer-CaMKIINtide inhibited theWnt5a induced in-
crease in PKC activity in a comparable manner toW-7. mer-CaMKIINtide
signiﬁcantly reduced stimulatory effects of Wnt5a on PKC activation
at 1.25 μM, and completely blocked the effect at 2.5 and 5 μM (Fig. 3B).
Wnt5a signiﬁcantly increased PKC activity in WT and shCamk2b
MC3T3-E1 cells, but this effect was prevented in shCamk2a cells
(Fig. 3C). PLAA antibody signiﬁcantly reduced the Wnt5a-induced
increase in PKC activity in MC3T3-E1 cells, whereas IgG had no ef-
fect (Fig. 3D). Similarly, Wnt5a increased PKC activity in MC3T3-E1
cells, and effect was blocked in shPlaa cells (Fig. 3E). PLA2 inhibitor
AACOCF3 signiﬁcantly reduced stimulatory effects of Wnt5a on
PKC activation at 0.1 μM, and completely blocked the effect at 1
and 10 μM (Fig. 3F).
3.4. Co-treatmentwithWnt5a and1α,25(OH)2D3 reduces PKC activation in
a dose-dependent manner
Given that both 1α,25(OH)2D3 and Wnt5a promote maturation of
osteoblasts and use Pdia3 to induce their effects, we tested the effects
of their co-treatment on the induction of their signaling pathways in
MC3T3-E1 osteoblast-like cells, speciﬁcally examining PKC activation.
In MC3T3-E1 cells, Wnt5a caused a 75% increase in PKC activity
(Fig. 4A). Addition of 1α,25(OH)2D3 reduced the stimulatory effect of
Wnt5a in a dose-dependent manner. At the highest concentration of
the hormone, PKC was increased by 30% in control cultures but the effect
of Wnt5a was abolished. The effect of Wnt5a on PKC in the presence of
1α,25(OH)2D3 also depended on Wnt5a concentration. Co-treatment
with 50 ng/ml Wnt5a caused a 2-fold increase in 1α,25(OH)2D3
stimulated PKC activity compared to cultures treated with only
1α,25(OH)2D3 (Fig. 4B). However, as the concentration of Wnt5a in-
creased, 1α,25(OH)2D3-stimulated PKC activation was suppressed.
3.5. ROR2, FZD2, and FZD5 are localized in caveolae and ROR2 is crucial for
1α,25(OH)2D3 membrane-mediated activation of PKC and CaMKII
Given, the key roles ROR2, FZD2 and FZD5 play in Wnt5a signaling,
we assessed their role on 1α,25(OH)2D3 stimulated rapid activation
of PKC and CaMKII. ROR2, but not FZD2 and FZD5 mediated the
1α,25(OH)2D3 stimulated rapid activation of PKC and CaMKII in
MC3T3-E1 osteoblasts-like cells. Anti-ROR2 antibody abolished the
1α,25(OH)2D3-dependent increase in PKC activity in MC3T3-E1 cells
(Fig. 5A), whereas, IgG had no effect. Conversely, blocking FZD2 and
FZD5 receptors had no effect on activation of PKC in response to
1α,25(OH)2D3 treatment. Similarly, anti-ROR2 antibody abolished the
Fig. 1. Effects of Wnt5a treatment on PKC, CaMKII, and PLA2 activation, and PGE2 release and growth zone chondrocytes (GC) (A) andMC3T3-E1 osteoblast-like cells (B). *p b 0.05, versus 0 ng/mlWnt5a; #p b 0.05, versus 50 ng/mlWnt5a; $p b 0.05,
versus 50 ng/mlWnt5a. Time-course ofWnt5a-induced PKC (C, G), CaMKII (D, H) and PLA2 (E, I) activation in GC (C–F) andMC3T3-E1 (G–J) cells. Treatment over control ratioswere calculated for each parameter. The dashed line represents the value
for the control cultures, which was set to 1. *p b 0.05, 1α,25(OH)2D3 treatment versus control; @p b 0.05, versus 6 min; #p b 0.05, versus 9 min; $p b 0.05, versus 6 min.
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Fig. 2. Effects of Pdia3, Vdr and Cav-1 silencing or blocking andβ-CD onWnt5a-stimulated activation of PKC inMC3T3-E1 cells.Wnt5a-induced PKC activation inwild-type (WT), shPdia3 (A),
shVdr (B) and shCav-1 (C) MC3T3-E1 cells. *p b 0.05, treatment versus control; #p b 0.05, versusWnt5a treatedWT. Effect of Pdia3 blocking (D) or VDR blocking (E) onWnt5a-induced PKC
activation. *p b 0.05, treatment versus control; #p b 0.05, versusWnt5a treated control group; $p b 0.05, versusWnt5a treated IgG group. (F) Effect of β-CD onWnt5a-inducedPKC activation.
Treatment over control ratios were calculated for each parameter. The dashed line represents the value for the control cultures, which was set to 1. *p b 0.05, treatment versus control.
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cells (Fig. 5B). Furthermore, anti-ROR2 antibody had no effect on
PLAA-induced CaMKII activation (Fig. 5C). Western blots of the plas-
ma membrane fractions of MC3T3-E1 cells indicated that ROR2,
FZD2, and FZD5 were present in the plasma membranes with their
greatest concentration in fraction 3, which represents caveolae mi-
crodomains (Fig. 5D).3.6. 1α,25(OH)2D3 alters the interactions between 1α,25(OH)2D3 receptor
complex and Wnt5a receptors
Immunoprecipitation studies conﬁrmed the interaction between
components of 1α,25(OH)2D3 receptor complex and Wnt5a recep-
tors. 1α,25(OH)2D3 treatment altered some of these interactions.
Samples of MC3T3-E1 whole cell lysates immunoprecipitated using
antibodies to Pdia3 (IP:Pdia3) were positive for FZD2, FZD5, and
ROR2 (Fig. 6A). Treatment with 1α,25(OH)2D3 for 15 min had no
effect on Pdia3:FRZ5 but increased Pdia3:FZD2 and Pdia3:ROR2.
Western blots of whole cell lysates immunoprecipitated with anti-
bodies to PLAA (IP:PLAA) demonstrated an increase in FZD2-
associated PLAA after addition of 1α,25(OH)2D3 (Fig. 6B). FZD5
and ROR2 interacted with PLAA, but 1α,25(OH)2D3 treatment had
no effect on these interactions. Cav-1 (IP:Cav-1) interacted with
FZD2, FZD5, and ROR2 (Fig. 6C). Treatment with 1α,25(OH)2D3 for
15 min had no effect on FZD2 and FZD5 but reduced ROR2. Immuno-
precipitation of CaM (IP:CaM) demonstrated interaction with FZD5
with or without 1α,25(OH)2D3 treatment (Fig. 6D). FZD2 and
ROR2 also interacted with CaM and 1α,25(OH)2D3 treatment re-
duced their interactions with CaM.3.7.Wnt5a alters the interactions between 1α,25(OH)2D3 receptor complex
and Wnt5a receptors
Immunoprecipitates of MC3T3-E1 whole cell lysates using antibodies
to Pdia3 (IP:Pdia3) were positive for FZD2 and FZD5 (Fig. 7A). Treatment
withWnt5a for 15min had no effect on FZD2's interactionwith Pdia3 but
increased FZD5. Western blots of whole cell lysates immunoprecipitated
with antibodies to PLAA (IP:PLAA) demonstrated interaction with FZD2
and FZD5 with and without 1α,25(OH)2D3 treatment (Fig. 7B). ROR2
also interacted with PLAA, and Wnt5a treatment reduced its interaction
with PLAA. Immunoprecipitation of Cav-1 (IP:Cav-1) demonstrated inter-
actions with FZD2, FZD5 and ROR2 (Fig. 7C). While Wnt5a treatment
reduced FZD2 and ROR2 interactions with Cav-1, it had no effect on
FZD5 interactions with Cav-1. Immunoprecipitation of CaM (IP:CaM)
demonstrated interaction with FRZD5 with or without Wnt5a treatment
(Fig. 7D). FZD2 and ROR2 also interacted with CaM. 1α,25(OH)2D3 treat-
ment increased FZD2 and CaM interaction and decreased ROR2 and CaM
interaction.4. Conclusions
This study demonstrates that signaling proteins critical for the
1α,25(OH)2D3 membrane-mediated pathway are also crucial for
Wnt5a calcium-dependent signaling. Events at the signaling level indi-
cated that Wnt5a calcium-dependent signaling works through a mech-
anism involving the CaMKII/PLA2/PGE2/PKC pathway. Moreover,
silencing or blocking of Pdia3, PLAA and VDR and inhibition of CaM,
CaMKII and PLA2 affected the activity of PKC in response toWnt5a treat-
ment. In contrast, PKC activity was unaffected in Cav-1 silenced cells,
Fig. 3. Effects of CaM, CaMKII, PLAA and PLA2 inhibition and Plaa, Camk2a and Camk2b silencing onWnt5a-stimulated activation of PKC inMC3T3-E1 cells. (A) Effect of CaM inhibition on
Wnt5a-induced PKC activation.. *p b 0.05, treatment versus control; #p b 0.05, versus 0 μMW-7+ Wnt5a; % p b 0.05, versus0.1 μMW-7+ Wnt5a. (B) Effect of CaMKII inhibition onWnt5a-
induced PKC activation. *p b 0.05, treatment versus control; #p b 0.05, versus 0 μMmer-CaMKIINtide + Wnt5a; $p b 0.05, versus 0.1 μMmer-CaMKIINtide + vehicle; % p b 0.05, versus
1.25 μMmer-CaMKIINtide + Wnt5a. (C) Effect of Wnt5a treatment on PKC activation in wild-type (WT), shCamk2a, and shCamk2b MC3T3-E1 cells. *p b 0.05, treatment versus control;
#p b 0.05, versus Wnt5a-treated WT; $p b 0.05, versusWnt5a treated shCamk2b; @p b 0.05, versus vehicle treated WT; %p b 0.05, versus vehicle treated shCamk2a. (D) Effect on PLAA
blocking on Wnt5a-induced PKC activation. *p b 0.05, treatment versus control; #p b 0.05, versusWnt5a treated control group; $p b 0.05, versusWnt5a treated IgG group. (E) Effect of
Plaa silencing on Wnt5-stimulated PKC activation. *p b 0.05, treatment versus control; #p b 0.05, versus Wnt5a-treated WT cells. (F) Effect of PLA2 inhibitor, AACOCF3, on Wnt5a-
inducedPKC activation. *p b 0.05, treatment versus control; #p b 0.05, versus 0 μM AACOCF3 + Wnt5a; $p b 0.05, 0 μM AACOCF3 + vehicle versus 0.1 μM AACOCF3 + Wnt5a.
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β-CD. Furthermore, Western blots of plasma membrane fractions indi-
cated that ROR2, FZD2, and FZD5 are localized in caveolae fraction.
Blocking of ROR2 abolished the stimulatory effects of 1α,25(OH)2D3
on PKC and CaMKII activations. This study also provides mechanistic
information by showing that the 1α,25(OH)2D3 receptor complex and
its downstream mediators form complexes with Wnt5a receptors, andFig. 4. Effect of 1α,25(OH)2D3 on Wnt5a-dependent PKC activation and effect of Wnt5a in
with 10−10, 10−9 and 10−8 M 1α,25(OH)2D3. Wnt5a was added to one-half of the cult
incubation, cell layers were collected for PKC assay. *p b 0.05, treatment versus control; #p b 0
@p b 0.05 versus 10−10 M 1α,25(OH)2D3 + Wnt5a. (B) MC3T3-E1 cells were treated with 10−
end of the incubation, the cell layers were collected for PKC assay. *p b 0.05, treatment versus con
Wnt5a; @p b 0.05 versus 1α,25(OH)2D3 + 5 ng/ml Wnt5a.these complexes respond to both 1α,25(OH)2D3 and Wnt5a treatment
by altering some of their protein–protein interactions.
Similar to 1α,25(OH)2D3 signaling, Wnt5a time course studies indi-
cate a rapid increase in CaMKII, PLA2 and PKC activities and PGE2 release
in GC chondrocytes and MC3T3-E1 osteoblast-like cells. While the pro-
ﬁles of time points at which Wnt5a activated PLA2 and triggered PGE2
release were similar between GC and MC3T3-E1 cells, differences1α,25(OH)2D3 regulation of PKC activity. (A) MC3T3-E1 cells were treated for 15 min
ures at the concentration of 125 ng/ml, at the time of the treatment. At the end of
.05, versus 0 M 1α,25(OH)2D3 + vehicle; $p b 0.05, versus 0 M 1α,25(OH)2D3 + Wnt5a;
8 M 1α,25(OH)2D3 in the presence and absence of 50, 87.5 and 125 ng/ml Wnt5a. At the
trol; #p b 0.05, versus 0 ng/ml Wnt5a + vehicle; $p b 0.05, versus 1α,25(OH)2D3 + 0 ng/ml
Fig. 5. Roles of FZD2, FZD5 and ROR2 in 1α,25(OH)2D3-dependent PKC activation and their subcellular localization. (A) Effects of FZD2, FZD5 or ROR2 blocking on 1α,25(OH)2D3-induced PKC
activation. *p b 0.05, treatment versus control; #p b 0.05, versus vehicle treated Control group; $p b 0.05, versus IgG + 1α,25(OH)2D3; %p b 0.05 versus FZD2 Ab + 1α,25(OH)2D3; ^p b 0.05
versus ROR2 Ab + 1α,25(OH)2D3. (B) Effect of ROR2 blocking on 1α,25(OH)2D3-inducedCaMKII activation. *p b 0.05, treatment versus control. (C) Effect of ROR2 blocking on PLAA
peptide-stimulated CaMKII activation. *pb 0.05, treatment versus control. (D) Subcellular localization of FZD2, FZD5 andROR2. Plasmamembrane fractionswere isolated as described. Presence
of FZD2, FZD5, ROR2 and Cav-1 in fractions was examined by Western blot. Each ﬁgure is a representative experiment repeated three times with similar results.
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contribute to such a difference is that while GC cells are primary carti-
lage cells isolated from the rat costochondral cartilage growth zone,
MC3T3-E1 osteoblast-like cells are a cell line derived from mouse
calvaria. The second potential reason for such an observation is that
growth zone chondrocytes used in these experiments were isolated
from 100–125 g male Sprague–Dawley rats, and these rats were at the
end of their adolescent growth spurt while the mouse osteoblast-like
MC3T3-E1 cell line was derived from a newborn mouse.
WhenGC andMC3T3-E1 cellswere treatedwithWnt5a, the increase
in PLA2 activity and PGE2 release occurred in a cyclic manner. A rapid
elevation was observed at 9 min after the treatment, whichwas follow-
ed by a decline at 15 min and a second increase at 30 min post Wnt5 a
treatment. The initial increase can be attributed to a rapid Wnt5a-
induced use of available factors required for activation of PLA2 and
downstreamPGE2 release, aswell as an increase in intracellular calcium
and activation of CaMKII [13,45,46]. The increase observed at 30 minFig. 6. Effect of 1α,25(OH)2D3 treatment on interactions between 1α,25(OH)2D3 receptor com
Whole cell lysates were isolated as described. (A) Pdia3 was immunoprecipitated and subjec
and anti-ROR2 antibodies. (B) PLAA was immunoprecipitated and subjected to Western blot. T
antibodies. (C) Cav-1 was immunoprecipitated and subjected to Western blot. The membran
(D) CaM was immunoprecipitated and subjected to Western blot. The membranes were incub
representative experiment repeated three times with similar results.might be the consequence of cross-talk with another pathway that in-
volves in activation of PLA2 or it could result from production of new
factors triggered by Wnt5a action. Previously, we reported that PLAA,
VDR, Cav-1 and caveolae are involved in 1α,25(OH)2D3 membrane-
mediated signaling by Pdia3 [9,12,40,47]. VDR has also been shown by
others to mediate rapid effects of 1α,25(OH)2D3 on Ca2+ transport via
voltage gated Ca2+ channels [48]. Similar to 1α,25(OH)2D3 membrane-
mediated signaling, our results indicated that Pdia3, PLAA, and VDR are
critical forWnt5a calcium-dependent pathway. However, to our surprise,
silenced Cav-1 osteoblasts activated PKC in response toWnt5a treatment,
suggesting that Cav-1 is not necessary for the Wnt5a calcium-dependent
pathway. To further investigate the role of lipid rafts in Wnt5a calcium-
dependent pathway, we subjected the cells to β-CD. PKC activity in-
creased in cells pretreated with β-CD but the increase was signiﬁcantly
lower than the β-CD-untreated group. Collectively, these studies indicate
thatWnt5a induces its effects partially via lipid rafts and caveolae are not
required to mediate Wnt5a effects. Previously, FZD5 and FZD2 proteinsplex and Wnt5a receptors. MC3T3-E1 cells were treated with 1α,25(OH)2D3 for 15 min.
ted to Western blot. The membranes were incubated with Ab Pdia3, Ab FZD2, anti-FZD5,
he membranes were incubated with the anti-PLAA, anti-FZD2, anti-FZD5, and anti-ROR2
es were incubated with the anti-Cav-1, anti-FZD2, anti-FZD5, and anti-ROR2 antibodies.
ated with the anti-CaM, anti-FZD2, anti-FZD5, and anti-ROR2 antibodies. Each ﬁgure is a
Fig. 7. Effect of Wnt5a treatment on interactions between 1α,25(OH)2D3 receptor complex andWnt5a receptors. MC3T3-E1 cells were treated withWnt5a for 15 min. Whole cell lysates
were isolated as described. (A) Pdia3 was immunoprecipitated and subjected to Western blot. The membranes were incubated with the anti-Pdia3, anti-FZD2 and anti-FZD5 antibodies.
(B) PLAA was immunoprecipitated and subjected to Western blot. The membranes were incubated with the anti-PLAA, anti-FZD2, anti-FZD5 and anti-ROR2 antibodies. (C) Cav-1 was
immunoprecipitated and subjected to Western blot. The membranes were incubated with the anti-Cav-1, anti-FZD2, anti-FZD5 and anti-ROR2 antibodies. (D) CaM was
immunoprecipitated and subjected to Western blot. The membranes were incubated with the anti-CaM, anti-FZD2, anti-FZD5 and anti-ROR2 antibodies. Each ﬁgure is a representative
experiment repeated three times with similar results.
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Wnt5a regulates its pathway via this group of lipid rafts [49].
Our inhibitor study indicates that CaM, CaMKII, and PLA2 are critical
for Wnt5a stimulated PKC activation. We previously reported that CaM
plays a critical role in 1α,25(OH)2D3membrane-mediated pathway and
its inhibition blocks 1α,25(OH)2D3 stimulated rapid activation of PKC
[13]. In the present study, we found that CaM inhibition by W-7
abolished Wnt5a stimulated activation of PKC in a dose-dependent
manner. Our hypothesis that CaM is required for Wnt5a stimulated ac-
tivation of PKC is also supported by the observation that CaM inhibition
suppresses PKC translocation in response to phorbol 12-myristate 13-
acetate (PMA) treatment in the rat aorta [50]. In our previous work,
we reported that CaMKII, isoform α, is necessary for 1α,25(OH)2D3
membrane stimulated activation of PLA2, PKC and PGE2 release [13].
Using mer-CaMKIINtide to inhibit the effect of CaMKII, we tested the
role of CaMKII in Wnt5a induced PKC activation. In the current study,
we found that CaMKII inhibition abolishedWnt5a stimulated activation
of PKC in a dose-dependent manner. Our hypothesis that CaMKII is
required forWnt5a induced activation of PKC is also supported by the ob-
servation that CaMKII regulates PLA2 activity [45]. PLA2 is known to act
upstream of PKC in several signaling pathways, including 1α,25(OH)2D3
and dihydrotestosterone [14,51], hence CaMKII inﬂuences PKC activity
in a PLA2-dependent mechanism. Additionally, in agreement with previ-
ous ﬁndings [14,51], we found that PLA2 inhibition abolished Wnt5a
induced activation of PKC in a dose-dependent manner.
MC3T3-E1 cells respond to 125ng/mlWnt5awith a rapid increase in
PKC activity. Here we report that co-treatment with 10−10–10−8 M
1α,25(OH)2D3 abrogates the increase in PKC activation seen with exog-
enous 125 ng/ml Wnt5a treatment alone, in a dose dependent manner.
Co-treatment of osteoblasts with 125 ng/ml Wnt5a and 10−8 M
1α,25(OH)2D3, returned PKC activity to the control level. Previously,
we reported that MC3T3-E1osteoblast-like cells respond to 10−8 M
1α,25(OH)2D3 with a rapid increase in PKC activity [9]. However, co-
treatment with 50-125 ng/ml Wnt5a leads to a strong increase in PKC
activity. Surprisingly, we observed that co-treatment with Wnt5a in-
duces enhanced effects on 1α,25(OH)2D3 stimulated PKC activation at
low dose of Wnt5a and repressive effects at high dose of Wnt5a. These
results may suggest that Wnt5a and 1α,25(OH)2D3 pathways compete
at their receptor complex or downstream pathway mediator levels.
Previously, we reported that 1α,25(OH)2D3 membrane associated
receptor, Pdia3, is present in plasma membrane compartments called
caveolae [52]. We also showed that PLAA and CaM are present in cave-
olae, where their interaction with Pdia3 receptor complex is critical for
transducing the 1α,25(OH)2D3 signal [12,13]. In the present study, our
plasma membrane fractionation experiment indicates that ROR2,
FZD2, and FZD5 are localized in fraction 3. Furthermore, our receptor
antibody blocking experiments shows that blocking ROR2 abolishes
1α,25(OH)2D3 stimulated PKC activation while blocking FZD2 andFZD5 receptors has no effect on activation of PKC in response
to 1α,25(OH)2D3 treatment. These results indicate that Wnt5a co-
receptor, ROR2, is part of 1α,25(OH)2D3 membrane-associate receptor
complex in caveolae. In agreement with our ﬁndings, another group
has detected ROR2 in Cav-1-α positive cholesterol-rich, detergent-
resistant microdomains (DRMs) of the plasma membrane in [53]. Fur-
thermore, they showed that ROR2 forms a complexwith bonemorpho-
genetic protein receptor type 1B (BMPR1B) in a ligand-independent
manner and it inhibited the growth and differentiation factor 5
(GDF5)/BMPR1B induced Smad 1/5 signaling pathway in ATDC5 cells
[54]. Collectively, these ﬁndings suggest that ROR2 participates in mul-
tiple signaling pathways including Wnt5a, BMP and 1α,25(OH)2D3.
Wnt5a induces its non-canonical signaling via several receptors.
ROR2 is a transmembrane receptor, previously identiﬁed to mediate
Wnt5a actions [55]. Wnt5a increases ROR2 expression, and knockdown
ofWNT5A dramatically decreases expression of ROR2 [30]. ROR2 has re-
gions of cysteine-rich domain that serve as its Wnt binding domain [56,
57]. Several conditions, including brachydactyly type B and autosomal
recessive Robinow syndrome, which display severe skeletal dysplasia,
are due to mutations in the ROR2 gene [58,59]. Additionally, ROR2 is
critically required for Wnt5a-induced migration of osteoblasts [60].
Wnt5a can also act via the Frizzled family of receptors. In human cells,
FZD2 and FZD5 are known to act as Wnt5a receptors and activate its
non-canonical signaling cascades [61,62].
Our CaM immunoprecipitation studies suggest that CaM forms a
complex with ROR2, FZD2, and FZD5. Wnt5a treatment does not alter
the interactions between CaM–FZD2 and CaM-FZD5, while it reduces
the interaction between CaM and ROR2. 1α,25(OH)2D3 treatment de-
creases the interactions between CaM–FZD2 and CaM–ROR2; however,
it does not alter the interactions between CaM and FZD5. These results
indicates that CaM serves as a mediator in both 1α,25(OH)2D3 and
Wnt5a pathways; suggesting its potential role to mediate the cross-
talk between these two pathways.
The results of this study suggest that Wnt5a and 1α,25(OH)2D3 me-
diate their effects via a network of interacting mediators rather than
through a secluded linear pathway. In co-treatment studies, we specu-
late that 1α,25(OH)2D3 receptor competes with Wnt5a receptors for
binding of PLAA, CaM and Cav-1, thus inhibiting downstream PKC sig-
naling. Previously, similar 1α,25(OH)2D3-induced mechanisms in
which one hormone can modulate the activity of a second, by compet-
ing for a shared mediator site, have been identiﬁed. Work from the
Ross lab has shown that retinoid X receptor (RXR)–vitamin D receptor
(VDR) and retinoid acid receptor (RAR)–RXR heterodimers compete
for a novel steroid hormone response element containing elements
responding to retinoid acid and 1α,25(OH)2D3 in the promoter region
of the avian β3 integrin gene [63]. Co-treatment with retinoid acid
and 1α,25(OH)2D3 resulted in a response equal to that of retinoid acid
alone [63]. Furthermore, their results indicated that RAR–RXR had a
2374 M. Doroudi et al. / Biochimica et Biophysica Acta 1843 (2014) 2365–2375greater afﬁnity for the shared promoter region than RXR–VDR, hence
co-addition of retinoid acid and 1α,25(OH)2D3 resulted in preferred
binding of RAR–RXR to the promoter and inhibition of 1α,25(OH)2D3
induced transcription [63]. Similar to this ﬁnding, our results also indi-
cated that Wnt5a and 1α,25(OH)2D3 compete for similar signaling me-
diators and co-treatment antagonizes the immunological effects of
1α,25(OH)2D3. 1α,25(OH)2D3 is known to stimulate alkaline phospha-
tase activity [16] and osteopontin production [9], markers of osteoblast
maturation, via its membrane-mediated events. Wnt5a has also been
shown to promote osteoblast differentiation and maturation. Wnt5a
treatment increases osteocalcin and osteoprotegerin levels and alkaline
phosphatase speciﬁc activity [26], while its knockout down regulates
osteoblastic differentiationmarkers including runt related transcription
factor 2, osterix and alkaline phosphatase [27]. Future studies should
focus on the in vivo consequences of the regulation of growth plate
chondrocytes growth and differentiation by Wnt5a and 1α,25(OH)2D3.
In conclusion, this study investigated the requirement for compo-
nents of 1α,25(OH)2D3 membrane-associated receptor complex in
Wnt5a calcium-dependent signaling. We found that Wnt5a stimulates
its calcium-dependent actions via Pdia3 receptor complex (Fig. 8). The
effects ofWnt5a aremediated through Pdia3, PLAA, and VDR. Inhibition
of CaM, CaMKII, and PLA2 suppressed the activation of PKC in response
to Wnt5a treatment. Silencing Cav-1 had no effect on Wnt5a-stimulated
PKC activation, which reveals one of the differences between the media-
tors of 1α,25(OH)2D3 and Wnt5a calcium-dependent pathways. Our re-
sults also showed that ROR2, one of the receptors of Wnt5a, plays an
important role in 1α,25(OH)2D3membrane-mediated signaling. Blocking
ROR2 abolished 1α,25(OH)2D3 induced PKC and CaMKII activations.
Moreover, immunoprecipitation studies showed that 1α,25(OH)2D3
membrane receptor complex (Pdia3, PLAA, Cav-1 and CaM) interacts
with Wnt5a receptors (ROR2, FZD2 and FZD5). While most of their pro-
tein–protein interactions were independent of either 1α,25(OH)2D3 or
Wnt5a treatment, a few of the interactions changed with ligands treat-
ments. In the co-treatment study, addition of 1α,25(OH)2D3 repressed
Wnt5a stimulated PKC activation in a dose-dependent manner. We
found that co-treatment with 1α,25(OH)2D3 repressed Wnt5a induced
PKC activation in a dose-dependent manner, and was most inhibited at
10−8 M. Furthermore, co-treatment with 50 ng/ml Wnt5a caused a
2-fold increase in 1α,25(OH)2D3 stimulated PKC activity compared to
cultures treated with only 1α,25(OH)2D3. However, as the concentration
of Wnt5a increased, it had repressive effects on 1α,25(OH)2D3-induced
PKC activation. The results of this study suggest that signaling
components of Pdia3 receptor complex are required for mediating
the calcium-dependent actions of Wnt5a and 1α,25(OH)2D3 may
modulate the response of Wnt5a by competing for similar signaling
mediators.Fig. 8. Proposed role of components of 1α,25(OH)2D3 membrane-associated receptor complex
PLAA and VDR (not shown). Inhibition of CaM, CaMKII, and PLA2 suppressed the activation ofAcknowledgments
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